Revenues and geographic information (Details 3) - USD ($)
$ in Millions |
3 Months Ended |
6 Months Ended |
Jun. 30, 2025 |
Jun. 30, 2024 |
Jun. 30, 2025 |
Jun. 30, 2024 |
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 14,054
|
$ 12,512
|
$ 27,287
|
$ 24,341
|
| Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
12.00%
|
|
12.00%
|
|
| Net sales, change in %, cc |
11.00%
|
|
13.00%
|
|
| Top 20 products [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 11,584
|
|
$ 22,421
|
|
| Top 20 products [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
16.00%
|
|
16.00%
|
|
| Net sales, change in %, cc |
14.00%
|
|
17.00%
|
|
| Rest of portfolio [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 2,470
|
|
$ 4,866
|
|
| Rest of portfolio [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(1.00%)
|
|
(3.00%)
|
|
| Net sales, change in %, cc |
(1.00%)
|
|
(1.00%)
|
|
| Cardiovascular, renal and metabolic [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 2,655
|
2,080
|
$ 5,173
|
4,110
|
| Cardiovascular, renal and metabolic [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
28.00%
|
|
26.00%
|
|
| Net sales, change in %, cc |
26.00%
|
|
26.00%
|
|
| Cardiovascular, renal and metabolic [member] | Entresto [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 2,357
|
1,898
|
$ 4,618
|
3,777
|
| Cardiovascular, renal and metabolic [member] | Entresto [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
24.00%
|
|
22.00%
|
|
| Net sales, change in %, cc |
22.00%
|
|
22.00%
|
|
| Cardiovascular, renal and metabolic [member] | Leqvio [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 298
|
182
|
$ 555
|
333
|
| Cardiovascular, renal and metabolic [member] | Leqvio [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
64.00%
|
|
67.00%
|
|
| Net sales, change in %, cc |
61.00%
|
|
66.00%
|
|
| Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Entresto [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 2,357
|
|
$ 4,618
|
|
| Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Entresto [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
24.00%
|
|
22.00%
|
|
| Net sales, change in %, cc |
22.00%
|
|
22.00%
|
|
| Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Leqvio [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 298
|
|
$ 555
|
|
| Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Leqvio [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
64.00%
|
|
67.00%
|
|
| Net sales, change in %, cc |
61.00%
|
|
66.00%
|
|
| Immunology [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 2,549
|
2,321
|
$ 4,958
|
4,402
|
| Immunology [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
10.00%
|
|
13.00%
|
|
| Net sales, change in %, cc |
9.00%
|
|
13.00%
|
|
| Immunology [member] | Cosentyx [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 1,629
|
1,526
|
$ 3,163
|
2,852
|
| Immunology [member] | Cosentyx [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
7.00%
|
|
11.00%
|
|
| Net sales, change in %, cc |
6.00%
|
|
11.00%
|
|
| Immunology [member] | Xolair [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 443
|
427
|
$ 899
|
826
|
| Immunology [member] | Xolair [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
4.00%
|
|
9.00%
|
|
| Net sales, change in %, cc |
2.00%
|
|
10.00%
|
|
| Immunology [member] | Ilaris [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 477
|
368
|
$ 896
|
724
|
| Immunology [member] | Ilaris [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
30.00%
|
|
24.00%
|
|
| Net sales, change in %, cc |
27.00%
|
|
24.00%
|
|
| Immunology [member] | Top 20 products [member] | Cosentyx [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 1,629
|
|
$ 3,163
|
|
| Immunology [member] | Top 20 products [member] | Cosentyx [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
7.00%
|
|
11.00%
|
|
| Net sales, change in %, cc |
6.00%
|
|
11.00%
|
|
| Immunology [member] | Top 20 products [member] | Xolair [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 443
|
|
$ 899
|
|
| Immunology [member] | Top 20 products [member] | Xolair [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
4.00%
|
|
9.00%
|
|
| Net sales, change in %, cc |
2.00%
|
|
10.00%
|
|
| Immunology [member] | Top 20 products [member] | Ilaris [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 477
|
|
$ 896
|
|
| Immunology [member] | Top 20 products [member] | Ilaris [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
30.00%
|
|
24.00%
|
|
| Net sales, change in %, cc |
27.00%
|
|
24.00%
|
|
| Neuroscience [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 1,457
|
1,225
|
$ 2,759
|
2,233
|
| Neuroscience [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
19.00%
|
|
24.00%
|
|
| Net sales, change in %, cc |
17.00%
|
|
23.00%
|
|
| Neuroscience [member] | Kesimpta [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 1,077
|
799
|
$ 1,976
|
1,436
|
| Neuroscience [member] | Kesimpta [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
35.00%
|
|
38.00%
|
|
| Net sales, change in %, cc |
33.00%
|
|
38.00%
|
|
| Neuroscience [member] | Zolgensma [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 297
|
349
|
$ 624
|
644
|
| Neuroscience [member] | Zolgensma [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(15.00%)
|
|
(3.00%)
|
|
| Net sales, change in %, cc |
(17.00%)
|
|
(3.00%)
|
|
| Neuroscience [member] | Aimovig [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 83
|
77
|
$ 159
|
153
|
| Neuroscience [member] | Aimovig [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
8.00%
|
|
4.00%
|
|
| Net sales, change in %, cc |
3.00%
|
|
3.00%
|
|
| Neuroscience [member] | Top 20 products [member] | Kesimpta [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 1,077
|
|
$ 1,976
|
|
| Neuroscience [member] | Top 20 products [member] | Kesimpta [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
35.00%
|
|
38.00%
|
|
| Net sales, change in %, cc |
33.00%
|
|
38.00%
|
|
| Neuroscience [member] | Top 20 products [member] | Zolgensma [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 297
|
|
$ 624
|
|
| Neuroscience [member] | Top 20 products [member] | Zolgensma [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(15.00%)
|
|
(3.00%)
|
|
| Net sales, change in %, cc |
(17.00%)
|
|
(3.00%)
|
|
| Oncology [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 4,293
|
3,527
|
$ 8,199
|
6,751
|
| Oncology [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
22.00%
|
|
21.00%
|
|
| Net sales, change in %, cc |
20.00%
|
|
22.00%
|
|
| Oncology [member] | Kisqali [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 1,177
|
717
|
$ 2,133
|
1,344
|
| Oncology [member] | Kisqali [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
64.00%
|
|
59.00%
|
|
| Net sales, change in %, cc |
64.00%
|
|
60.00%
|
|
| Oncology [member] | Tafinlar + Mekinist [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 573
|
523
|
$ 1,125
|
997
|
| Oncology [member] | Tafinlar + Mekinist [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
10.00%
|
|
13.00%
|
|
| Net sales, change in %, cc |
7.00%
|
|
13.00%
|
|
| Oncology [member] | Promacta/Revolade [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 502
|
544
|
$ 1,048
|
1,064
|
| Oncology [member] | Promacta/Revolade [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(8.00%)
|
|
(2.00%)
|
|
| Net sales, change in %, cc |
(9.00%)
|
|
(1.00%)
|
|
| Oncology [member] | Jakavi [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 524
|
471
|
$ 1,016
|
949
|
| Oncology [member] | Jakavi [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
11.00%
|
|
7.00%
|
|
| Net sales, change in %, cc |
8.00%
|
|
8.00%
|
|
| Oncology [member] | Pluvicto [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 454
|
345
|
$ 825
|
655
|
| Oncology [member] | Pluvicto [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
32.00%
|
|
26.00%
|
|
| Net sales, change in %, cc |
30.00%
|
|
26.00%
|
|
| Oncology [member] | Tasigna [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 327
|
446
|
$ 704
|
841
|
| Oncology [member] | Tasigna [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(27.00%)
|
|
(16.00%)
|
|
| Net sales, change in %, cc |
(27.00%)
|
|
(15.00%)
|
|
| Oncology [member] | Scemblix [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 298
|
164
|
$ 536
|
300
|
| Oncology [member] | Scemblix [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
82.00%
|
|
79.00%
|
|
| Net sales, change in %, cc |
79.00%
|
|
78.00%
|
|
| Oncology [member] | Lutathera [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 207
|
175
|
$ 400
|
344
|
| Oncology [member] | Lutathera [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
18.00%
|
|
16.00%
|
|
| Net sales, change in %, cc |
17.00%
|
|
16.00%
|
|
| Oncology [member] | Piqray/Vijoice [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 111
|
120
|
$ 211
|
229
|
| Oncology [member] | Piqray/Vijoice [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(8.00%)
|
|
(8.00%)
|
|
| Net sales, change in %, cc |
(8.00%)
|
|
(8.00%)
|
|
| Oncology [member] | Fabhalta [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 120
|
22
|
$ 201
|
28
|
| Oncology [member] | Top 20 products [member] | Kisqali [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 1,177
|
|
$ 2,133
|
|
| Oncology [member] | Top 20 products [member] | Kisqali [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
64.00%
|
|
59.00%
|
|
| Net sales, change in %, cc |
64.00%
|
|
60.00%
|
|
| Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 573
|
|
$ 1,125
|
|
| Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
10.00%
|
|
13.00%
|
|
| Net sales, change in %, cc |
7.00%
|
|
13.00%
|
|
| Oncology [member] | Top 20 products [member] | Promacta/Revolade [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 502
|
|
$ 1,048
|
|
| Oncology [member] | Top 20 products [member] | Promacta/Revolade [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(8.00%)
|
|
(2.00%)
|
|
| Net sales, change in %, cc |
(9.00%)
|
|
(1.00%)
|
|
| Oncology [member] | Top 20 products [member] | Jakavi [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 524
|
|
$ 1,016
|
|
| Oncology [member] | Top 20 products [member] | Jakavi [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
11.00%
|
|
7.00%
|
|
| Net sales, change in %, cc |
8.00%
|
|
8.00%
|
|
| Oncology [member] | Top 20 products [member] | Pluvicto [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 454
|
|
$ 825
|
|
| Oncology [member] | Top 20 products [member] | Pluvicto [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
32.00%
|
|
26.00%
|
|
| Net sales, change in %, cc |
30.00%
|
|
26.00%
|
|
| Oncology [member] | Top 20 products [member] | Tasigna [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 327
|
|
$ 704
|
|
| Oncology [member] | Top 20 products [member] | Tasigna [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(27.00%)
|
|
(16.00%)
|
|
| Net sales, change in %, cc |
(27.00%)
|
|
(15.00%)
|
|
| Oncology [member] | Top 20 products [member] | Scemblix [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 298
|
|
$ 536
|
|
| Oncology [member] | Top 20 products [member] | Scemblix [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
82.00%
|
|
79.00%
|
|
| Net sales, change in %, cc |
79.00%
|
|
78.00%
|
|
| Oncology [member] | Top 20 products [member] | Lutathera [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 207
|
|
$ 400
|
|
| Oncology [member] | Top 20 products [member] | Lutathera [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
18.00%
|
|
16.00%
|
|
| Net sales, change in %, cc |
17.00%
|
|
16.00%
|
|
| Established Brands [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 3,100
|
3,359
|
$ 6,198
|
6,845
|
| Established Brands [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(8.00%)
|
|
(9.00%)
|
|
| Net sales, change in %, cc |
(8.00%)
|
|
(8.00%)
|
|
| Established Brands [member] | Sandostatin Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 303
|
313
|
$ 620
|
668
|
| Established Brands [member] | Sandostatin Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(3.00%)
|
|
(7.00%)
|
|
| Net sales, change in %, cc |
(3.00%)
|
|
(6.00%)
|
|
| Established Brands [member] | Exforge Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 191
|
178
|
$ 370
|
370
|
| Established Brands [member] | Exforge Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
7.00%
|
|
0.00%
|
|
| Net sales, change in %, cc |
7.00%
|
|
3.00%
|
|
| Established Brands [member] | Lucentis [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 173
|
275
|
$ 362
|
589
|
| Established Brands [member] | Lucentis [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(37.00%)
|
|
(39.00%)
|
|
| Net sales, change in %, cc |
(39.00%)
|
|
(38.00%)
|
|
| Established Brands [member] | Diovan Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 154
|
160
|
$ 304
|
300
|
| Established Brands [member] | Diovan Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(4.00%)
|
|
1.00%
|
|
| Net sales, change in %, cc |
(4.00%)
|
|
3.00%
|
|
| Established Brands [member] | Galvus Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 123
|
150
|
$ 247
|
299
|
| Established Brands [member] | Galvus Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(18.00%)
|
|
(17.00%)
|
|
| Net sales, change in %, cc |
(17.00%)
|
|
(14.00%)
|
|
| Established Brands [member] | Kymriah [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 99
|
113
|
$ 199
|
233
|
| Established Brands [member] | Kymriah [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(12.00%)
|
|
(15.00%)
|
|
| Net sales, change in %, cc |
(14.00%)
|
|
(15.00%)
|
|
| Established Brands [member] | Contract manufacturing [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 276
|
271
|
$ 619
|
550
|
| Established Brands [member] | Contract manufacturing [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
2.00%
|
|
13.00%
|
|
| Net sales, change in %, cc |
(3.00%)
|
|
12.00%
|
|
| Established Brands [member] | Other [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 1,781
|
1,899
|
$ 3,477
|
3,836
|
| Established Brands [member] | Other [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(6.00%)
|
|
(9.00%)
|
|
| Net sales, change in %, cc |
(5.00%)
|
|
(7.00%)
|
|
| Established Brands [member] | Top 20 products [member] | Sandostatin Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 303
|
|
$ 620
|
|
| Established Brands [member] | Top 20 products [member] | Sandostatin Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(3.00%)
|
|
(7.00%)
|
|
| Net sales, change in %, cc |
(3.00%)
|
|
(6.00%)
|
|
| Established Brands [member] | Top 20 products [member] | Exforge Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 191
|
|
$ 370
|
|
| Established Brands [member] | Top 20 products [member] | Exforge Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
7.00%
|
|
0.00%
|
|
| Net sales, change in %, cc |
7.00%
|
|
3.00%
|
|
| Established Brands [member] | Top 20 products [member] | Lucentis [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 173
|
|
$ 362
|
|
| Established Brands [member] | Top 20 products [member] | Lucentis [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(37.00%)
|
|
(39.00%)
|
|
| Net sales, change in %, cc |
(39.00%)
|
|
(38.00%)
|
|
| Established Brands [member] | Top 20 products [member] | Diovan Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 154
|
|
$ 304
|
|
| Established Brands [member] | Top 20 products [member] | Diovan Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(4.00%)
|
|
1.00%
|
|
| Net sales, change in %, cc |
(4.00%)
|
|
3.00%
|
|
| Established Brands [member] | Top 20 products [member] | Galvus Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 123
|
|
$ 247
|
|
| Established Brands [member] | Top 20 products [member] | Galvus Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(18.00%)
|
|
(17.00%)
|
|
| Net sales, change in %, cc |
(17.00%)
|
|
(14.00%)
|
|
| US |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 6,249
|
$ 5,146
|
$ 11,961
|
$ 9,734
|
| US | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
21.00%
|
|
23.00%
|
|
| Net sales, change in %, cc |
21.00%
|
|
23.00%
|
|
| US | Top 20 products [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 5,630
|
|
$ 10,746
|
|
| US | Top 20 products [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
22.00%
|
|
24.00%
|
|
| US | Rest of portfolio [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 619
|
|
$ 1,215
|
|
| US | Rest of portfolio [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
13.00%
|
|
11.00%
|
|
| US | Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Entresto [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 1,223
|
|
$ 2,392
|
|
| US | Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Entresto [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
29.00%
|
|
26.00%
|
|
| US | Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Leqvio [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 138
|
|
$ 265
|
|
| US | Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Leqvio [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
47.00%
|
|
58.00%
|
|
| US | Immunology [member] | Top 20 products [member] | Cosentyx [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 921
|
|
$ 1,736
|
|
| US | Immunology [member] | Top 20 products [member] | Cosentyx [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
6.00%
|
|
14.00%
|
|
| US | Immunology [member] | Top 20 products [member] | Ilaris [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 260
|
|
$ 478
|
|
| US | Immunology [member] | Top 20 products [member] | Ilaris [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
34.00%
|
|
33.00%
|
|
| US | Neuroscience [member] | Top 20 products [member] | Kesimpta [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 713
|
|
$ 1,300
|
|
| US | Neuroscience [member] | Top 20 products [member] | Kesimpta [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
28.00%
|
|
34.00%
|
|
| US | Neuroscience [member] | Top 20 products [member] | Zolgensma [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 96
|
|
$ 225
|
|
| US | Neuroscience [member] | Top 20 products [member] | Zolgensma [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(28.00%)
|
|
(5.00%)
|
|
| US | Oncology [member] | Top 20 products [member] | Kisqali [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 750
|
|
$ 1,336
|
|
| US | Oncology [member] | Top 20 products [member] | Kisqali [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
100.00%
|
|
94.00%
|
|
| US | Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 246
|
|
$ 454
|
|
| US | Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
22.00%
|
|
18.00%
|
|
| US | Oncology [member] | Top 20 products [member] | Promacta/Revolade [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 227
|
|
$ 515
|
|
| US | Oncology [member] | Top 20 products [member] | Promacta/Revolade [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(20.00%)
|
|
(6.00%)
|
|
| US | Oncology [member] | Top 20 products [member] | Pluvicto [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 358
|
|
$ 645
|
|
| US | Oncology [member] | Top 20 products [member] | Pluvicto [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
21.00%
|
|
12.00%
|
|
| US | Oncology [member] | Top 20 products [member] | Tasigna [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 162
|
|
$ 359
|
|
| US | Oncology [member] | Top 20 products [member] | Tasigna [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(30.00%)
|
|
(11.00%)
|
|
| US | Oncology [member] | Top 20 products [member] | Scemblix [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 191
|
|
$ 345
|
|
| US | Oncology [member] | Top 20 products [member] | Scemblix [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
82.00%
|
|
79.00%
|
|
| US | Oncology [member] | Top 20 products [member] | Lutathera [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 150
|
|
$ 289
|
|
| US | Oncology [member] | Top 20 products [member] | Lutathera [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
21.00%
|
|
20.00%
|
|
| US | Established Brands [member] | Top 20 products [member] | Sandostatin Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 187
|
|
$ 384
|
|
| US | Established Brands [member] | Top 20 products [member] | Sandostatin Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
0.00%
|
|
(10.00%)
|
|
| US | Established Brands [member] | Top 20 products [member] | Exforge Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 1
|
|
$ 3
|
|
| US | Established Brands [member] | Top 20 products [member] | Exforge Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
0.00%
|
|
(40.00%)
|
|
| US | Established Brands [member] | Top 20 products [member] | Diovan Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 7
|
|
$ 20
|
|
| US | Established Brands [member] | Top 20 products [member] | Diovan Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
17.00%
|
|
33.00%
|
|
| Rest of the world [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 7,805
|
|
$ 15,326
|
|
| Rest of the world [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
6.00%
|
|
5.00%
|
|
| Net sales, change in %, cc |
4.00%
|
|
6.00%
|
|
| Rest of the world [member] | Top 20 products [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 5,954
|
|
$ 11,675
|
|
| Rest of the world [member] | Top 20 products [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
10.00%
|
|
9.00%
|
|
| Net sales, change in %, cc |
7.00%
|
|
10.00%
|
|
| Rest of the world [member] | Rest of portfolio [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 1,851
|
|
$ 3,651
|
|
| Rest of the world [member] | Rest of portfolio [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(5.00%)
|
|
(7.00%)
|
|
| Net sales, change in %, cc |
(5.00%)
|
|
(5.00%)
|
|
| Rest of the world [member] | Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Entresto [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 1,134
|
|
$ 2,226
|
|
| Rest of the world [member] | Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Entresto [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
19.00%
|
|
18.00%
|
|
| Net sales, change in %, cc |
15.00%
|
|
18.00%
|
|
| Rest of the world [member] | Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Leqvio [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 160
|
|
$ 290
|
|
| Rest of the world [member] | Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Leqvio [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
82.00%
|
|
76.00%
|
|
| Net sales, change in %, cc |
74.00%
|
|
74.00%
|
|
| Rest of the world [member] | Immunology [member] | Top 20 products [member] | Cosentyx [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 708
|
|
$ 1,427
|
|
| Rest of the world [member] | Immunology [member] | Top 20 products [member] | Cosentyx [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
8.00%
|
|
8.00%
|
|
| Net sales, change in %, cc |
6.00%
|
|
9.00%
|
|
| Rest of the world [member] | Immunology [member] | Top 20 products [member] | Xolair [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 443
|
|
$ 899
|
|
| Rest of the world [member] | Immunology [member] | Top 20 products [member] | Xolair [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
4.00%
|
|
9.00%
|
|
| Net sales, change in %, cc |
2.00%
|
|
10.00%
|
|
| Rest of the world [member] | Immunology [member] | Top 20 products [member] | Ilaris [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 217
|
|
$ 418
|
|
| Rest of the world [member] | Immunology [member] | Top 20 products [member] | Ilaris [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
25.00%
|
|
15.00%
|
|
| Net sales, change in %, cc |
20.00%
|
|
15.00%
|
|
| Rest of the world [member] | Neuroscience [member] | Top 20 products [member] | Kesimpta [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 364
|
|
$ 676
|
|
| Rest of the world [member] | Neuroscience [member] | Top 20 products [member] | Kesimpta [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
49.00%
|
|
45.00%
|
|
| Net sales, change in %, cc |
45.00%
|
|
45.00%
|
|
| Rest of the world [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 201
|
|
$ 399
|
|
| Rest of the world [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(7.00%)
|
|
(2.00%)
|
|
| Net sales, change in %, cc |
(10.00%)
|
|
(2.00%)
|
|
| Rest of the world [member] | Oncology [member] | Top 20 products [member] | Kisqali [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 427
|
|
$ 797
|
|
| Rest of the world [member] | Oncology [member] | Top 20 products [member] | Kisqali [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
25.00%
|
|
21.00%
|
|
| Net sales, change in %, cc |
25.00%
|
|
24.00%
|
|
| Rest of the world [member] | Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 327
|
|
$ 671
|
|
| Rest of the world [member] | Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
2.00%
|
|
10.00%
|
|
| Net sales, change in %, cc |
(2.00%)
|
|
10.00%
|
|
| Rest of the world [member] | Oncology [member] | Top 20 products [member] | Promacta/Revolade [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 275
|
|
$ 533
|
|
| Rest of the world [member] | Oncology [member] | Top 20 products [member] | Promacta/Revolade [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
5.00%
|
|
3.00%
|
|
| Net sales, change in %, cc |
3.00%
|
|
5.00%
|
|
| Rest of the world [member] | Oncology [member] | Top 20 products [member] | Jakavi [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 524
|
|
$ 1,016
|
|
| Rest of the world [member] | Oncology [member] | Top 20 products [member] | Jakavi [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
11.00%
|
|
7.00%
|
|
| Net sales, change in %, cc |
8.00%
|
|
8.00%
|
|
| Rest of the world [member] | Oncology [member] | Top 20 products [member] | Pluvicto [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 96
|
|
$ 180
|
|
| Rest of the world [member] | Oncology [member] | Top 20 products [member] | Pluvicto [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
92.00%
|
|
128.00%
|
|
| Net sales, change in %, cc |
80.00%
|
|
125.00%
|
|
| Rest of the world [member] | Oncology [member] | Top 20 products [member] | Tasigna [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 165
|
|
$ 345
|
|
| Rest of the world [member] | Oncology [member] | Top 20 products [member] | Tasigna [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(24.00%)
|
|
(21.00%)
|
|
| Net sales, change in %, cc |
(25.00%)
|
|
(19.00%)
|
|
| Rest of the world [member] | Oncology [member] | Top 20 products [member] | Scemblix [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 107
|
|
$ 191
|
|
| Rest of the world [member] | Oncology [member] | Top 20 products [member] | Scemblix [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
81.00%
|
|
79.00%
|
|
| Net sales, change in %, cc |
76.00%
|
|
77.00%
|
|
| Rest of the world [member] | Oncology [member] | Top 20 products [member] | Lutathera [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 57
|
|
$ 111
|
|
| Rest of the world [member] | Oncology [member] | Top 20 products [member] | Lutathera [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
12.00%
|
|
8.00%
|
|
| Net sales, change in %, cc |
6.00%
|
|
6.00%
|
|
| Rest of the world [member] | Established Brands [member] | Top 20 products [member] | Sandostatin Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 116
|
|
$ 236
|
|
| Rest of the world [member] | Established Brands [member] | Top 20 products [member] | Sandostatin Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(8.00%)
|
|
(2.00%)
|
|
| Net sales, change in %, cc |
(8.00%)
|
|
0.00%
|
|
| Rest of the world [member] | Established Brands [member] | Top 20 products [member] | Exforge Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 190
|
|
$ 367
|
|
| Rest of the world [member] | Established Brands [member] | Top 20 products [member] | Exforge Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
7.00%
|
|
1.00%
|
|
| Net sales, change in %, cc |
8.00%
|
|
4.00%
|
|
| Rest of the world [member] | Established Brands [member] | Top 20 products [member] | Lucentis [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 173
|
|
$ 362
|
|
| Rest of the world [member] | Established Brands [member] | Top 20 products [member] | Lucentis [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(37.00%)
|
|
(39.00%)
|
|
| Net sales, change in %, cc |
(39.00%)
|
|
(38.00%)
|
|
| Rest of the world [member] | Established Brands [member] | Top 20 products [member] | Diovan Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 147
|
|
$ 284
|
|
| Rest of the world [member] | Established Brands [member] | Top 20 products [member] | Diovan Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(5.00%)
|
|
0.00%
|
|
| Net sales, change in %, cc |
(6.00%)
|
|
1.00%
|
|
| Rest of the world [member] | Established Brands [member] | Top 20 products [member] | Galvus Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 123
|
|
$ 247
|
|
| Rest of the world [member] | Established Brands [member] | Top 20 products [member] | Galvus Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(18.00%)
|
|
(17.00%)
|
|
| Net sales, change in %, cc |
(17.00%)
|
|
(14.00%)
|
|